Sphingosine Kinase 1 in Breast Cancer—A New Molecular Marker and a Therapy Target

Por Alshaker, Heba, Thrower, Hannah, Pchejetski, Dmitri
Publicado no Front Oncol (2020)

Transcriptome-Wide Effects of Sphingosine Kinases Knockdown in Metastatic Prostate and Breast Cancer Cells: Implications for Therapeutic Targeting

Por Alshaker, Heba, Wang, Qi, Brewer, Daniel, Pchejetski, Dmitri
Publicado no Front Pharmacol (2019)

Bradycardia and syncope as sole manifestations of a cranial lesion: a case report

Por Pchejetski, Dmitri, Kenbaz, Mojiba, Alshaker, Heba, Jesudason, Kiruparajan
Publicado no J Med Case Rep (2020)

The emerging role of FTY720 (Fingolimod) in cancer treatment

Por White, Christopher, Alshaker, Heba, Cooper, Colin, Winkler, Matthias, Pchejetski, Dmitri
Publicado no Oncotarget (2016)

An unusual case of disseminated intravascular coagulation

Por Pchejetski, Dmitri, Kenbaz, Mojiba, Alshaker, Heba, Rajput, Dharmesh, Jesudason, Kiruparajan
Publicado no Oxf Med Case Reports (2017)

Dynamic early identification of hip replacement implants with high revision rates. Study based on the NJR data from UK during 2004-2012

Por Begun, Alexander, MacGregor, Alexander J., Pchejetski, Dmitri, Kulinskaya, Elena
Publicado no PLoS One (2020)

Leptin signalling, obesity and prostate cancer: molecular and clinical perspective on the old dilemma

Por Alshaker, Heba, Sacco, Keith, Alfraidi, Albandri, Muhammad, Aun, Winkler, Mathias, Pchejetski, Dmitri
Publicado no Oncotarget (2015)

Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer

Por Pchejetski, Dmitri, Alfraidi, Albandri, Sacco, Keith, Alshaker, Heba, Muhammad, Aun, Monzon, Leonardo
Publicado no J Cancer Res Clin Oncol (2015)

New FTY720-docetaxel nanoparticle therapy overcomes FTY720-induced lymphopenia and inhibits metastatic breast tumour growth

Por Alshaker, Heba, Wang, Qi, Srivats, Shyam, Chao, Yimin, Cooper, Colin, Pchejetski, Dmitri
Publicado no Breast Cancer Res Treat (2017)

Core shell lipid-polymer hybrid nanoparticles with combined docetaxel and molecular targeted therapy for the treatment of metastatic prostate cancer

Por Wang, Qi, Alshaker, Heba, Böhler, Torsten, Srivats, Shyam, Chao, Yimin, Cooper, Colin, Pchejetski, Dmitri
Publicado no Sci Rep (2017)

Field template-based design and biological evaluation of new sphingosine kinase 1 inhibitors

Por Alshaker, Heba, Srivats, Shyam, Monteil, Danielle, Wang, Qi, Low, Caroline M. R., Pchejetski, Dmitri
Publicado no Breast Cancer Res Treat (2018)

Leptomeningeal carcinomatosis as the primary presentation of relapse in breast cancer

Por Sacco, Keith, Muhammad, Aun, Saleem, Waqar, Alshaker, Heba, Monzon, Leonardo, Islam, Mohammad Rafiqul, Pchejetski, Dmitri
Publicado no Oncol Lett (2016)

Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1

Por Alshaker, Heba, Wang, Qi, Kawano, Yoshiaki, Arafat, Tawfiq, Böhler, Torsten, Winkler, Mathias, Cooper, Colin, Pchejetski, Dmitri
Publicado no Oncotarget (2016)

Combination of RAD001 (everolimus) and docetaxel reduces prostate and breast cancer cell VEGF production and tumour vascularisation independently of sphingosine-kinase-1

Por Alshaker, Heba, Wang, Qi, Böhler, Torsten, Mills, Robert, Winkler, Mathias, Arafat, Tawfiq, Kawano, Yoshiaki, Pchejetski, Dmitri
Publicado no Sci Rep (2017)

Leptin induces upregulation of sphingosine kinase 1 in oestrogen receptor-negative breast cancer via Src family kinase-mediated, janus kinase 2-independent pathway

Por Alshaker, Heba, Krell, Jonathan, Frampton, Adam E, Waxman, Jonathan, Blyuss, Oleg, Zaikin, Alexey, Winkler, Mathias, Stebbing, Justin, Yagüe, Ernesto, Pchejetski, Dmitri
Publicado no Breast Cancer Res (2014)